Effect of Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance
- 1 August 2017
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 19 (8) , 471-475
Abstract
Background: Impaired glucose tolerance (IGT) and glycemic variability may be associated with increased risk of micro- and macrovascular complications. The aim of this study was to assess the effect of linagliptin versus metformin on glycemic variability in patients with IGT. Material and Methods: A randomized, double-blind clinical trial with parallel groups was carried out in 16 adult patients with IGT, overweight or obesity. All patients signed an informed consent. The therapies were randomly assigned: (a) metformin 500 mg bid (n = 8) or (b) linagliptin 5 mg a.m. and placebo p.m. (n = 8), both for 90 days. At the beginning of the trial and 3 months later, fasting glucose, glycated hemoglobin A1c, oral glucose tolerance test (OGTT), and glycemic variability [area under the curve (AUC) of glucose, mean amplitude of glycemic excursion (MAGE), standard deviation (SD) of glucose, coefficient of variation (CV) of glucose, and mean blood glucose (MBG)] were measured. Mann–Whitney U, Wilcoxon, and Fisher exact tests were used for statistical analyses. Results: Both groups were similar in basal characteristics. After linagliptin administration, a significant decrease in glucose levels at 120 min of OGTT (9.0 ± 0.9 vs. 6.9 ± 2.2 mmol/L, P = 0.012) was observed. Glycemic variability showed a similar behavior and there were no significant differences in the AUC, MAGE, SD of glucose, CV of glucose, and MBG between groups. Conclusion: Linagliptin administration resulted in better glycemic control according to the decrease of glucose levels by the OGTT at 120 min in patients with IGT. Meanwhile, glycemic variability was not modified in any of the study groups.Keywords
This publication has 15 references indexed in Scilit:
- Molecular mechanism of action of metformin: old or new insights?Diabetologia, 2013
- Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitusEndocrine, 2012
- Glucose Variability; Does It Matter?Endocrine Reviews, 2010
- Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad conceptDiabetes/Metabolism Research and Reviews, 2009
- Continuous Glucose Monitoring and Diabetes Health Outcomes: A Critical AppraisalDiabetes Technology & Therapeutics, 2008
- Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose ToleranceDiabetes Care, 2008
- The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting GlucoseDiabetes Care, 2008
- Dipeptidyl Peptidase-4 InhibitorsDiabetes Care, 2007
- Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and interventionDiabetic Medicine, 2002
- Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?European Journal of Clinical Investigation, 2000